{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032436","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.431716+00:00","generated_at":"2026-06-21T18:01:07.241827+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Elite Pharmaceuticals Q2 FY2023: Revenue $16.3M (+4% YoY), Net Income $1.82M","bullets":["Consolidated six-month revenue $16.3M, up 4% YoY vs prior year.","Operating profit $2.1M; net income $1.82M for the six-month period.","Revenue growth attributed to generic immediate-release and extended-release Adderall.","Conference call on Nov 15, 2022 at 11:30 AM EST; dial-in 1-800-346-7359."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032436","json":"https://secwatch.observer/filing/0001493152-22-032436.json","markdown":"https://secwatch.observer/filing/0001493152-22-032436.md","text":"https://secwatch.observer/filing/0001493152-22-032436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222032436/0001493152-22-032436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315222032436/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:01:07.241827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}